Zotefoams PLC (ZTF)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 477.50 |
|---|---|
| 52-week range | 318.55 – 513.14 |
| Return, 1 month / 3 months | +12.0% / +5.0% |
| Return, 1 year / 3 years | +11.9% / +81.7% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 38.0% |
| Worst drawdown (1 year) | -28.2% |
| Average daily value traded | 54.55M GBX |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Zotefoams PLC is a British manufacturer of lightweight cellular foams based in Croydon, England. The company produces polyolefin and fluoropolymer foams using a high-pressure nitrogen gas process, marketing them under names such as AZOTE and ZOTEK. These foams are used for insulation, cushioning, buoyancy and protection in markets including aerospace, automotive, medical, sports and packaging, and the company also supplies foam products for footwear and other industrial applications.
The shares are listed on the London Exchange in UK under the code ZTF, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Zotefoams PLC (ZTF) trades on the London Exchange in UK. It last closed at GBX 477.50 on 23 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 936 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.9% and over the last three months it rose 5.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.3% | ||
| From 52-week high | -4.5% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 5.0% | ||
| 6-month return | 22.5% | ||
| 12-month return, skipping the last month | 0.0% | ||
| Stability (higher is calmer) | 48 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.2% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 54.55M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 34 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −4.5% |
|---|---|
| 1 month | +12.0% |
| 3 months | +5.0% |
| 6 months | +22.5% |
| 1 year | +11.9% |
| 3 years | +81.7% |
| 5 years | +47.7% |
Signals
| 50-day / 200-day average | 447.44 / 417.59 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 19.26 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Sep 2026 | GBP 0.0263 |
| 30 Apr 2026 | GBP 0.0535 |
| 4 Sep 2025 | GBP 0.0250 |
| 1 May 2025 | GBP 0.0510 |
| 5 Sep 2024 | GBP 0.0238 |
| 2 May 2024 | GBP 0.0490 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.